Drug
Cisplatin clinical trials
Also written Platinol, CDDP, cis-DDP and NSC 119875.
Includes 3 studies of S-1 plus cisplatin and 3 studies of Cisplatin Liposomal.
- studies test it
- 1,652
- open now
- 223
- in phase 3
- 280
- first study started
- 1990
Keep track of what changes. Save the Cisplatin studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Name
- Cisplatin
- 1,223
- DDP
- 155
- Platinol-AQ
- 147
- Cisplatinum
- 126
Development codes
Other names
- CDDP
- 222
Combined with it in one product
Studies by the year they started
1,636 studies that test it; most in 2009 (81); 2 more planned to start later
| Year | Studies |
|---|---|
| 1990 | 1 |
| 1991 | 3 |
| 1992 | 1 |
| 1993 | 5 |
| 1994 | 11 |
| 1995 | 8 |
| 1996 | 14 |
| 1997 | 30 |
| 1998 | 33 |
| 1999 | 47 |
| 2000 | 35 |
| 2001 | 40 |
| 2002 | 55 |
| 2003 | 78 |
| 2004 | 54 |
| 2005 | 58 |
| 2006 | 61 |
| 2007 | 75 |
| 2008 | 79 |
| 2009 | 81 |
| 2010 | 65 |
| 2011 | 61 |
| 2012 | 43 |
| 2013 | 54 |
| 2014 | 49 |
| 2015 | 67 |
| 2016 | 62 |
| 2017 | 62 |
| 2018 | 42 |
| 2019 | 41 |
| 2020 | 51 |
| 2021 | 49 |
| 2022 | 42 |
| 2023 | 49 |
| 2024 | 63 |
| 2025 | 34 |
| 2026 | 33 |
By phase
A phase 1/2 study counts in both.
- Early Phase 1
- 12
- Phase 1
- 429
- Phase 2
- 1,039
- Phase 3
- 280
- Phase 4
- 18
- No phase
- 46
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 262 · Other 1,390
National Cancer Institute (NCI) (76) · Memorial Sloan Kettering Cancer Center (59) · Eli Lilly and Company (50) · M.D. Anderson Cancer Center (44) · Sun Yat-sen University (42) · Gynecologic Oncology Group (34) · Dana-Farber Cancer Institute (27) · Fudan University (25)
Often tested with
Tested in the same studies.
Gemcitabine (368) · Paclitaxel (269) · Docetaxel (201) · Carboplatin (180) · Fluorouracil (171) · Etoposide (148) · Pemetrexed (138) · Doxorubicin (81)
Studies
Open first, then newest update. How each study uses Cisplatin is read from its arms, and is right about nine times in ten.
Testing it · 1,652
- Biomarker Based Neoadjuvant Strategies for Locally Advanced Resectable ESCCRecruitingPhase 2Fujian Medical University Union HospitalNCT06601309Written as Paclitaxel+Cisplatin(Concurrent Chemoradiotherapy)
- Combined Systemic and Intraperitoneal Chemotherapy for Synchronous Gastric and/or Gastroesophageal Peritoneal CarcinomatosisRecruitingPhase 2Mohammad Haroon Asif ChoudryNCT07475286Written as Cisplatin
- Coronary MicrovAscular Diseases Intervention With Compound Danshen Dropping PillsNot yet recruitingPhase 4Qilu Hospital of Shandong UniversityNCT07885462Written as Compound Danshen Dripping Pills
- Neoadjuvant and Adjuvant Treatment in Resectable Non-small Cell Lung CancerRecruitingPhase 2AstraZenecaNCT05061550Written as Cisplatin
- Testing the Addition of BMS-986016 (Relatlimab) to the Usual Immunotherapy After Initial Treatment for Recurrent or Metastatic Nasopharyngeal CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06029270Written as Cisplatin
- Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic AlterationsRecruitingPhase 1/2AbbVieNCT06772623Written as Cisplatin
- Histotripsy in Biliary Tract CancerRecruitingNot applicableNYU Langone HealthNCT07853690Written as Cisplatin
- Study of RAS(ON) Inhibitors in Patients With Advanced RAS-mutated NSCLCRecruitingPhase 1/2Revolution Medicines, Inc.NCT06162221Written as Cisplatin
- PDT For Induction Therapy For Head And Neck CancerRecruitingPhase 2Massachusetts General HospitalNCT07214987Written as Cisplatin
- PD-1 Blockade Alone Versus in Combination With Chemotherapy as First Line Therapy in Females With Advanced NSCLC & PD-L1 Expression ≥50%Not yet recruitingPhase 3German Cancer Research CenterNCT07877584Written as Cisplatin (75 mg/m²)
- Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingPhase 1National Cancer Institute (NCI)NCT04847063Written as Cisplatin
- A Prospective, Multi-Center, Phase 4, Single Arm Study To Assess The Safety and Tolerability of Perioperative Durvalumab in Combination With Neoadjuvant Gemcitabine Plus Cisplatin in Indian Patients With Muscle-Invasive Bladder Cancer Cle-InvasiveNot yet recruitingPhase 4AstraZenecaNCT07876817Written as Cisplatin
- Iparomlimab/Tuvonralimab Combined With Nab-paclitaxel and Cisplatin as Neoadjuvant Therapy for Locally Advanced Cervical CancerRecruitingPhase 2Xijing HospitalNCT07876154Written as Cisplatin
- A Study Using Nivolumab, in Combination With Chemotherapy Drugs to Treat Nasopharyngeal Carcinoma (NPC)RecruitingPhase 2National Cancer Institute (NCI)NCT06064097Written as Cisplatin
- Testing the Addition of MEDI4736 (Durvalumab) to Chemotherapy Before Surgery for Patients With High-Grade Upper Urinary Tract CancerRecruitingPhase 2/3National Cancer Institute (NCI)NCT04628767Written as Cisplatin
- A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic CholangiocarcinomaRecruitingPhase 2M.D. Anderson Cancer CenterNCT05967182Written as Cisplatin
- A Phase II Study of Single Tremelimumab With Regular Interval Durvalumab Plus Gemcitabine and Cisplatin in Locally Advanced Unresectable/Metastatic Combined Hepatocellular-cholangiocarcinomaNot yet recruitingPhase 2Mehmet AkceNCT06855225Written as Cisplatin
- De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNARecruitingPhase 2Mayo ClinicNCT05541016Written as Cisplatin
- A Platform Study in Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 1/2AstraZenecaNCT06996782Written as Cisplatin
- Gemcitabine, Cisplatin and Nab-Paclitaxel as Neoadjuvant Treatment for Patients With Resectable or Borderline Resectable Pancreatic CancerRecruitingPhase 2Georgetown UniversityNCT06423326Written as Cisplatin
See all 1,652 studies that test Cisplatin →
Given in every arm · 1,039 — Cisplatin is usual care beside what is tested
- A UGT1A1 Genotype-Directed Study of Belinostat Pharmacokinetics and ToxicityRecruitingPhase 2National Cancer Institute (NCI)NCT06406465Written as Cisplatin
- Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingPhase 3National Cancer Institute (NCI)NCT04267848Written as Cisplatin
- A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus Chemotherapy for Stage IV/Recurrent Non-squamous Non-small Cell Lung Cancer With PD-L1 Expression ≥ 1%RecruitingPhase 3Bristol-Myers SquibbNCT06561386Written as Cisplatin
- Durvalumab + Intraductal Radiofrequency Ablation (ID-RFA) in Extra- and Intrahepatic CholangiocarcinomaRecruitingPhase 2Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestNCT06440993Written as Cisplatin
- Evaluating the Addition of the Immunotherapy Drug Atezolizumab to Standard Chemotherapy Treatment for Advanced or Metastatic Neuroendocrine Carcinomas That Originate Outside the LungRecruitingPhase 2/3National Cancer Institute (NCI)NCT05058651Written as Cisplatin
- Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER StudyRecruitingPhase 3NRG OncologyNCT07097142Written as Cisplatin
- A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherapy Versus Placebo Plus Pembrolizumab and Chemotherapy in First-line Metastatic Non-small Cell Lung Cancer Participants With Homozygous MTAP DeletionRecruitingPhase 2/3Bristol-Myers SquibbNCT07063745Written as Cisplatin
- A Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pumitamig and PDCT as First-line Treatment for Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)RecruitingPhase 2Bristol-Myers SquibbNCT07680764Written as Cisplatin
- Induction Pembrolizumab and Chemotherapy Followed by Pembrolizumab Before Chemoradiation and Pembrolizumab Maintenance Compared to Standard Chemoradiation With Pembrolizumab Followed by Pembrolizumab Maintenance in High-Risk Cervical CancerRecruitingPhase 3National Cancer Institute (NCI)NCT07061977Written as Cisplatin
- Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk NeuroblastomaRecruitingPhase 3National Cancer Institute (NCI)NCT06172296Written as Cisplatin
- A Clinical Study of MK-2870 Alone or With Other Treatments to Treat Gastrointestinal Cancers (MK-9999-02A)RecruitingPhase 1/2Merck Sharp & Dohme LLCNCT06428409Written as Cisplatin
- A Safety and Efficacy Study of EIK1001 in Combination With Pembrolizumab and Chemotherapy in Participants With Stage 4 Non-Small Cell Lung Cancer.RecruitingPhase 2/3Eikon TherapeuticsNCT07365319Written as Pemetrexed + Cisplatin /Carboplatin
- SKB500 Combinations in Patients With Esophageal Squamous Cell CarcinomaRecruitingPhase 2Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.NCT07700667Written as Cisplatin
- CR-001 in Adult Participants With Locally Advanced or Metastatic Solid TumorsRecruitingPhase 1/2Crescent Biopharma, Inc.NCT07335497Written as Cisplatin
- A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NECNot yet recruitingPhase 3Nanjing Leads Biolabs Co.,LtdNCT07720193Written as Cisplatin injection
- Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerRecruitingPhase 2National Cancer Institute (NCI)NCT06223568Written as Cisplatin
- A Clinical Trial of LBL-024 Combination Drug in Patients With Advanced Solid Tumours[Substudy 02(BTC&HCC)]RecruitingPhase 2Nanjing Leads Biolabs Co.,LtdNCT07111546Written as Cisplatin Injection
- A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06623422Written as Cisplatin
- Window of Opportunity in Preserving Laryngeal Function TrialRecruitingPhase 2Matthew SpectorNCT07423078Written as Cisplatin
- A Study of ASP3082 in Adults With Advanced Solid TumorsRecruitingPhase 1Astellas Pharma IncNCT05382559Written as Cisplatin
Showing 20 of 1,039.
As the comparator · 228 — what is tested is compared with Cisplatin
- Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell CarcinomaRecruitingPhase 2National Cancer Institute (NCI)NCT04671667Written as Cisplatin
- Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC TrialRecruitingPhase 2National Cancer Institute (NCI)NCT06770582Written as Cisplatin
- Enfortumab Vedotin in Combination With Pembrolizumab vs. Concurrent Chemoradiotherapy (cCRT) in People With Muscle Invasive Bladder Cancer (EV-309)RecruitingPhase 3Astellas Pharma Global Development, Inc.NCT07566156Written as Cisplatin
- A Phase Ⅲ Study of Rilvegostomig in Combination With Fluoropyrimidine and Trastuzumab Deruxtecan as the First-line Treatment for HER2-positive Gastric CancerRecruitingPhase 3AstraZenecaNCT06764875Written as Cisplatin
- A Study to Assess Adverse Events, Change in Disease Activity and Optimal Dose of Intravenous (IV) Telisotuzumab Adizutecan With IV Pembrolizumab for First-Line Treatment of Adult Participants With Recurrent or Metastatic Head and Neck Squamous Cell CarcinomaRecruitingPhase 2AbbVieNCT07744126Written as Cisplatin
- A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingPhase 3BayerNCT06452277Written as Cisplatin
- A Study to Assess Efficacy and Safety of Pembrolizumab With or Without Sacituzumab Tirumotecan (MK- 2870) in Adult Participants With Resectable Non Small Cell Lung Cancer (NSCLC) Not Achieving Pathological Complete Response (pCR) (MK-2870-019)RecruitingPhase 3Merck Sharp & Dohme LLCNCT06312137Written as Cisplatin
- Phase 3 Study of T-DXd and Rilvegostomig Versus SoC in Advanced HER2-expressing Biliary Tract CancerRecruitingPhase 3AstraZenecaNCT06467357Written as Cisplatin
- Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)RecruitingPhase 2/3Bristol-Myers SquibbNCT07100080Written as Cisplatin
- Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Monotherapy or Osimertinib in Combination With Platinum-based Chemotherapy for EGFRmt Non-small Cell Lung Cancer (IZABRIGHT-Lung02)RecruitingPhase 3Bristol-Myers SquibbNCT07680790Written as Cisplatin
- A Clinical Study of Calderasib (MK-1084) and Other Treatments for Participants With Non-Small Cell Lung Cancer (MK-1084-007/KANDLELIT-007)RecruitingPhase 3Merck Sharp & Dohme LLCNCT07190248Written as Cisplatin
- A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung CancerRecruitingPhase 3Hoffmann-La RocheNCT06793215Written as Cisplatin
- A Study Comparing the Combination of Pembrolizumab and Sacituzumab Govitecan-hziy Versus Standard of Care in the Treatment of Advanced Urothelial CancerRecruitingPhase 3National Cancer Institute (NCI)NCT06524544Written as Cisplatin
- ImmunoADC Therapy for Induction Conversion in Patients With Stage IVB OSCC/OPSCCNot yet recruitingPhase 2Huashan HospitalNCT07844551Written as Cisplatin
- A Study of Amivantamab in Addition to Standard of Care Agents (SOC) Compared With SOC Alone in Participants With Recurrent/Metastatic Head and Neck CancerRecruitingPhase 3Janssen Research & Development, LLCNCT07276399Written as Cisplatin
- Refining Adjuvant Treatment IN Endometrial Cancer Based On Molecular Features (RAINBO) - NSMP-ORANGE Trial: Comparing Radiotherapy With Oral Progestin Tablets vs. the Current Standard Care, Radiotherapy and Chemotherapy, in Patients With NSMP Endometrial CancerRecruitingPhase 3University College, LondonNCT07831902Written as Cisplatin
- Serplulimab Combined With Induction Chemotherapy and Radiotherapy in Nasopharyngeal CarcinomaRecruitingPhase 3Union Hospital, Tongji Medical College, Huazhong University of Science and TechnologyNCT07177443Written as Cisplatin
- A Study of BL-B01D1 With or Without PD-1 Monoclonal Antibody in Patients With High-Risk Locally Advanced Nasopharyngeal CarcinomaNot yet recruitingPhase 2Sichuan Baili Pharmaceutical Co., Ltd.NCT07797881Written as Cisplatin
- Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on OsimertinibRecruitingPhase 1/2Genprex, Inc.NCT04486833Written as Platinum-Based Chemotherapy
- First-line Treatment With RC48 Plus Sintilimab and S-1 in Advanced Gastric Cancer (RCTS2)RecruitingPhase 2Qilu Hospital of Shandong UniversityNCT06730373Written as Cisplatin
Showing 20 of 228.
Codes
What other systems call Cisplatin · ClinicalTrials.gg INT007223
- MeSH (NLM) D002945CisplatinConfirmed NLM, Wikidata
- UNII (FDA) Q20Q21Q62JCISPLATINConfirmed FDA, NLM, Wikidata
- RxNorm 2555Confirmed FDA, Wikidata
- Wikidata Q412415cisplatinConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C376CisplatinOne source FDA
- DrugBank DB00515One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | D002945 | Cisplatin | Confirmed NLM, Wikidata |
| UNII (FDA) | Q20Q21Q62J | CISPLATIN | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2555 | — | Confirmed FDA, Wikidata |
| Wikidata | Q412415 | cisplatin | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C376 | Cisplatin | One source FDA |
| DrugBank | DB00515 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.